{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:04:57Z","timestamp":1791428697757,"version":"4.3.3"},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T00:00:00Z","timestamp":1410307200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0107434","type":"journal-article","created":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T17:59:20Z","timestamp":1410371960000},"page":"e107434","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":115,"title":["Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients"],"prefix":"10.1371","volume":"9","author":[{"given":"Niels H.","family":"Skotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber L.","family":"Southwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Warby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal N.","family":"Doty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Petoukhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuljeet","family":"Vaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Kordasiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Freier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punit P.","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Frank","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric E.","family":"Swayze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,9,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.25717","article-title":"Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk","volume":"29","author":"ER Fisher","year":"2013","journal-title":"Mov Disord"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/jmedgenet-2013-101796","article-title":"CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease","volume":"50","author":"A Semaka","year":"2013","journal-title":"J Med Genet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular Mechanisms and Potential Therapeutical Targets in Huntington\u2019s Disease","volume":"90","author":"C Zuccato","year":"2010","journal-title":"Physiological Reviews"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jmg.31.5.377","article-title":"Instability of CAG repeats in Huntington\u2019s disease: relation to parental transmission and age of onset","volume":"31","author":"Y Trottier","year":"1994","journal-title":"J Med Genet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/hmg\/3.12.2103","article-title":"DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence","volume":"3","author":"F Squitieri","year":"1994","journal-title":"Hum Mol Genet"},{"key":"ref6","first-page":"16","article-title":"Phenotypic characterization of individuals with 30\u201340 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36\u201339 repeats","volume":"59","author":"DC Rubinsztein","year":"1996","journal-title":"The American Journal of Human Genetics"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/306234a0","article-title":"A polymorphic DNA marker genetically linked to Huntington\u2019s disease","volume":"306","author":"JF Gusella","year":"1983","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u201cs disease chromosomes. The Huntington\u201ds Disease Collaborative Research Group","volume":"72","year":"1993","journal-title":"Cell"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.brainresbull.2006.10.027","article-title":"Comprehensive care in Huntington\u201cs disease: a physician\u201ds perspective","volume":"72","author":"MA Nance","year":"2007","journal-title":"Brain Research Bulletin"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11940-013-0219-8","article-title":"Treatment of huntington disease","volume":"15","author":"A Videnovic","year":"2013","journal-title":"Curr Treat Options Neurol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S6430","article-title":"Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease","volume":"6","author":"S Frank","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(11)70070-9","article-title":"Development of biomarkers for Huntington\u2019s disease","volume":"10","author":"DW Weir","year":"2011","journal-title":"Lancet Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.nbd.2005.08.007","article-title":"Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models","volume":"21","author":"RK Graham","year":"2006","journal-title":"Neurobiology of Disease"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease","volume":"101","author":"A Yamamoto","year":"2000","journal-title":"Cell"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"J Nasir","year":"1995","journal-title":"Cell"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.7618107","article-title":"Inactivation of the mouse Huntington\u2019s disease gene homolog Hdh","volume":"269","author":"MP Duyao","year":"1995","journal-title":"Science"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue","volume":"11","author":"S Zeitlin","year":"1995","journal-title":"Nature Genetics"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ng1297-404","article-title":"Huntingtin is required for neurogenesis and is not impaired by the Huntington\u2019s disease CAG expansion","volume":"17","author":"JK White","year":"1997","journal-title":"Nature Genetics"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","article-title":"Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice","volume":"26","author":"I Dragatsis","year":"2000","journal-title":"Nature Genetics"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model","volume":"102","author":"SQ Harper","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington\u2019s Disease","volume":"19","author":"JL McBride","year":"2011","journal-title":"Molecular Therapy"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"M DiFiglia","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained Therapeutic Reversalof Huntington\u2019s Disease by Transient Repression of Huntingtin Synthesis","volume":"74","author":"HB Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington&apos;ns Disease Mice","volume":"17","author":"RL Boudreau","year":"2009","journal-title":"Molecular Therapy"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtinsilencing","volume":"65","author":"V Drouet","year":"2009","journal-title":"Ann Neurol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"J Hu","year":"2009","journal-title":"Nat Biotechnol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","article-title":"Allele-Selective Inhibition of Mutant HuntingtinExpression with Antisense Oligonucleotides Targeting the Expanded CAG Repeat","volume":"49","author":"KT Gagnon","year":"2010","journal-title":"Biochemistry"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.chembiol.2010.10.013","article-title":"Allele-Selective Inhibition of Huntingtin Expression by Switching to an miRNA-like RNAi Mechanism","volume":"17","author":"J Hu","year":"2010","journal-title":"Chemistry & Biology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1471-4159.2008.05734.x","article-title":"Allele-specific silencing of mutant Huntington\u2019s disease gene","volume":"108","author":"Y Zhang","year":"2009","journal-title":"Journal of Neurochemistry"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/hum.2007.116","article-title":"Identification and Allele-Specific Silencing of the Mutant Huntingtin Allele in Huntington\u2019s Disease Patient-Derived Fibroblasts","volume":"19","author":"PHJ van Bilsen","year":"2008","journal-title":"Human Gene Therapy"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington\u2019s disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"MS Lombardi","year":"2009","journal-title":"Experimental Neurology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington\u2022s Disease Patients","volume":"19","author":"EL Pfister","year":"2009","journal-title":"Current Biology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene\/Allele-Specific Silencing of Mutant Huntingtin","volume":"19","author":"JB Carroll","year":"2011","journal-title":"Molecular Therapy"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"ME Ostergaard","year":"2013","journal-title":"Nucleic Acids Research"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1749-6632.2009.04975.x","article-title":"Allele-Selective Inhibition of Mutant Huntingtin by Peptide Nucleic Acid-Peptide Conjugates, Locked Nucleic Acid, and Small Interfering RNA","volume":"1175","author":"J Hu","year":"2009","journal-title":"Annals of the New York Academy of Sciences"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"D Yu","year":"2012","journal-title":"Cell"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1093\/nar\/gkt594","article-title":"RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression","volume":"41","author":"J Liu","year":"2013","journal-title":"Nucleic Acids Research"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/nat.2013.0476","article-title":"Exploring the Effect of Sequence Length and Composition on Allele-Selective Inhibition of Human Huntingtin Expression by Single-Stranded Silencing RNAs","volume":"24","author":"J Hu","year":"2014","journal-title":"Nucleic Acid Therapeutics"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00401235","article-title":"Juvenile Huntington disease","volume":"73","author":"JG van Dijk","year":"1986","journal-title":"Hum Genet"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e4f8606b742ef3","DOI":"10.1371\/4f8606b742ef3","article-title":"The Prevalence of Juvenile Huntington\u2019s Disease: A Review of the Literature and Meta-Analysis","volume":"4","author":"O Quarrell","year":"2012","journal-title":"PLoS Curr"},{"key":"ref41","article-title":"Personalized gene silencing therapeutics for Huntington disease","author":"C Kay","year":"2014","journal-title":"Clin Genet"},{"key":"ref42","article-title":"Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity","author":"X Sun","year":"2014","journal-title":"Hum Mol Genet"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"J Hu","year":"2009","journal-title":"Nat Biotechnol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","article-title":"CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing Haplogroup","volume":"84","author":"SC Warby","year":"2009","journal-title":"The American Journal of Human Genetics"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.molmed.2012.09.001","article-title":"Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases","volume":"18","author":"AL Southwell","year":"2012","journal-title":"Trends in Molecular Medicine"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform","volume":"50","author":"CF Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"MA Passini","year":"2011","journal-title":"Science Translational Medicine"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"TM Miller","year":"2013","journal-title":"Lancet Neurol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0022-3565(24)38893-7","article-title":"Antisense-mediated down-regulation of the human huntingtin gene","volume":"295","author":"RJ Boado","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/mcne.2000.0872","article-title":"Inhibition of Huntingtin Synthesis by Antisense Oligodeoxynucleotides","volume":"16","author":"C Nellemann","year":"2000","journal-title":"Molecular and Cellular Neuroscience"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/hmg\/dds397","article-title":"A fully humanized transgenic mouse model of Huntington disease","volume":"22","author":"AL Southwell","year":"2013","journal-title":"Hum Mol Genet"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s10495-009-0405-z","article-title":"Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways","volume":"14","author":"Z Zhang","year":"2009","journal-title":"Apoptosis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/9304","article-title":"Crystal structure and improved antisense properties of 2\u2032-O-(2-methoxyethyl)-RNA","volume":"6","author":"M Teplova","year":"1999","journal-title":"Nat Struct Biol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.0.CO;2-8","article-title":"Thrombin is an extracellular signal that activates intracellular death protease pathways inducing apoptosis in model motor neurons","volume":"36","author":"IV Smirnova","year":"1998","journal-title":"J Neurobiol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm801294h","article-title":"Short Antisense Oligonucleotides with Novel 2\u2032\u22124\u2032 Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals","volume":"52","author":"PP Seth","year":"2009","journal-title":"J Med Chem"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1093\/nar\/gks273","article-title":"TricycloDNA-modified oligo-2\u2032-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues\u2013a comparative study of oligonucleotide length, design and chemistry","volume":"40","author":"S Murray","year":"2012","journal-title":"Nucleic Acids Research"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.molcel.2007.08.015","article-title":"Structure of Human RNase H1 Complexed with an RNA\/DNA Hybrid: Insight into HIV Reverse Transcription","volume":"28","author":"M Nowotny","year":"2007","journal-title":"Molecular Cell"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","article-title":"Evaluation of 2\u201c-modified oligonucleotides containing 2-\u201ddeoxy gaps as antisense inhibitors of gene expression","volume":"268","author":"BP Monia","year":"1993","journal-title":"J Biol Chem"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a Central Nervous System Delivered 2\u2032-O-Methoxyethyl-Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates","volume":"350","author":"F Rigo","year":"2014","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"9570","DOI":"10.1093\/nar\/gkt693","article-title":"ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy","volume":"41","author":"J Liu","year":"2013","journal-title":"Nucleic Acids Research"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1021\/bi4014209","article-title":"Allele-Selective Inhibition of Expression of Huntingtin and Ataxin-3 by RNA Duplexes Containing Unlocked Nucleic Acid Substitutions","volume":"52","author":"Y Aiba","year":"2013","journal-title":"Biochemistry"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1093\/nar\/gkp587","article-title":"Improvement of RNA secondary structure prediction using RNase H cleavage and randomized oligonucleotides","volume":"37","author":"AD Kauffmann","year":"2009","journal-title":"Nucleic Acids Research"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"18191","DOI":"10.1074\/jbc.272.29.18191","article-title":"The Influence of Antisense Oligonucleotide-induced RNA Structure on Escherichia coli RNase H1 Activity","volume":"272","author":"WF Lima","year":"1997","journal-title":"Journal of Biological Chemistry"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"RA Smith","year":"2006","journal-title":"J Clin Invest"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nbt.2376","article-title":"Assessing unintended hybridization-induced biological effects of oligonucleotides","volume":"30","author":"M Lindow","year":"2012","journal-title":"Nat Biotechnol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"JK Watts","year":"2011","journal-title":"J Pathol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington\u2019s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"JG Hodgson","year":"1999","journal-title":"Neuron"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0107434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T15:36:29Z","timestamp":1746372989000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0107434"}},"subtitle":[],"editor":[{"given":"Joseph C.","family":"Glorioso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,10]]},"references-count":67,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0107434","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,10]]}}}